Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,107
Out of 4,820 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $39.74 | +5.69% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $183.35 | +104.53% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $80.89 | +42.17% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $94.89 | -3.05% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $17.91 | -33.00% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $14.39 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $30.00 | +200.00% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $224.70 | +20.16% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $96.68 | -29.66% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $12.35 | +264.37% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $135.13 | +103.51% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $18.03 | +105.21% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $71.66 | -16.27% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $101.91 | -65.66% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $260.59 | -68.92% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $39.74
Upside: +5.69%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $183.35
Upside: +104.53%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $80.89
Upside: +42.17%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $94.89
Upside: -3.05%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $17.91
Upside: -33.00%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $14.39
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $30.00
Upside: +200.00%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $224.70
Upside: +20.16%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $96.68
Upside: -29.66%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $12.35
Upside: +264.37%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $135.13
Upside: +103.51%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $18.03
Upside: +105.21%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $71.66
Upside: -16.27%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $101.91
Upside: -65.66%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $260.59
Upside: -68.92%